Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? [Yahoo! Finance]
Neuropace, Inc. (NPCE)
Company Research
Source: Yahoo! Finance
fully into its core responsive neurostimulation franchise, where reimbursement and pricing actions are improving unit economics. At the same time, management is still funding growth. Commercial and research and development spending remain elevated, and procedure timing can swing quarterly results even when demand signals look strong. NPCE Beats Q1 Estimates, Raises Outlook First-quarter 2026 revenues were $22.1 million, down 2% year over year, but the mix mattered. Core RNS System revenues were $21.7 million, up 19.5% year over year, while service revenues were $314,000 and DIXI Medical contributed just $0.1 million during the wind-down. Losses also improved. Adjusted loss per share narrowed to 13 cents from 18 cents a year ago, and adjusted operating loss improved to $3.3 million from $4.1 million. Management raised full-year 2026 revenue guidance to $99 million-$101 million (up from $98 million-$100 million) on a continuing-operations basis. The margin commentary was equal
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistantâ„¢ [Yahoo! Finance]Yahoo! Finance
- NeuroPace (NPCE) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Here's Why You Should Add NeuroPace Stock to Your Portfolio Now [Yahoo! Finance]Yahoo! Finance
- How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target [Yahoo! Finance]Yahoo! Finance
- NeuroPace Announces FDA Approval of ECoG Assistantâ„¢, Advancing AI-Driven Epilepsy Care [Yahoo! Finance]Yahoo! Finance
NPCE
Earnings
- 5/12/26 - Miss
NPCE
Sec Filings
- 6/25/26 - Form 4
- 6/22/26 - Form 4
- 6/22/26 - Form 4
- NPCE's page on the SEC website